Proportion of patients achieving clinical response and each MMS category at week 12 stratified according to baseline disease activity (pooled data from ELEVATE UC 52 and ELEVATE UC 12). Lines extending from each corner are representative of each disease activity subgroup in this analysis. Patients with moderately active disease (MMS 5–7) at baseline are reflected in the lines extending from the top of the diagram with patients with severely active disease (MMS 8–9) at baseline reflected in the lines extending from the bottom of the diagram. The left and right sides represent patients treated with etrasimod and placebo, respectively. Line thickness reflects the proportions of patients who achieved clinical response (dark green line) and the proportions of patients with different levels of disease activity at week 12 (severe [red]—low [light green]; each arrow points to a decrease in disease activity). ^aClinical response was defined as a ≥2-point and ≥30% decrease from baseline in MMS, and a ≥1-point decrease from baseline in RBS or RBS ≤ 1. ^bMMS was not available for some patients at week 12 for various reasons, including discontinuation prior to week 12. Abbreviations: MMS, modified Mayo score; RBS, rectal bleeding subscore; UC, ulcerative colitis.